Antibody Discovery
Brochure: Get to the Clinic First with Best-In-Class Antibody Therapeutics
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Brochure: Lead Molecules Against Any Target. At Record Pace.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.
Customer Spotlight: Genovac on Antibody Discovery
Find out how Genovac is delivering 10-fold more lead candidates against difficult targets.
Webinar: Looking to the Future: What’s next in Antibody Therapeutics
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Webinar: Accelerating Discovery and Development of Antibody Therapeutics
Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.
App Note: Discover Lead Molecules Against Difficult Targets Inaccessible by Hybridoma Methods
Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.
Datasheet: Opto™ Plasma B Discovery 4.0
Review workflow overview and representative results.
Product Tour: The Opto™ Plasma B Discovery 4.0 Workflow
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ Plasma B Discover workflow makes it possible to accelerate lead molecule discovery against difficult targets.
Webinar: Tackle Difficult Targets by Accessing Broad B Cell Diversity
Watch our presentation at AE&T Digital Week, hosted with Genovac, to hear how the Beacon system is making it possible to find 10 times more lead candidates than hybridoma in just days.
Webinar: A Beacon for Rapid Antibody Discovery against Difficult Targets
Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Application Note: Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates
Explore case studies for the rapid discovery of antibodies against challenging targets.
Customer Spotlight: Abveris on Antibody Discovery
Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.
Customer Spotlight: Amgen on AbD and CLD
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Webinar: Rapid Discovery of a Diverse Panel of Antibodies Against Membrane Targets Using the Beacon System
Dr. Shireen Khan presents a case study on how ChemPartner has leveraged the Beacon system to rapidly discover cross-reactive antibodies against the GPI-anchored uPA receptor.
Webinar: Rapid Discovery of Functional Antibodies for SARS-CoV-2 Using the Beacon System
Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, describe how they have used the Beacon platform, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.
SynBioBeta Live Roundtable: Can Humanity Build a Global Antibody Defense Barrier Against Future Pandemics?
Listen to the world’s leading experts on antibody discovery to discuss how we can build a global defensive barrier to find new therapeutic antibodies against the coronavirus and future pathogens.
Datasheet: Opto Plasma B Discovery 2.0 Workflow
Review workflow overview and representative results.